GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: cagrilintide stopped being a problem at week 75 — 47 comments in the full submission. View in context.
1.4k
c/cagrilintide·submitted 2 years ago by u/yannick_petrov

small win: cagrilintide stopped being a problem at week 75

Labbranch of 6 comments

small win: cagrilintide stopped being a problem at week 75. Numbers below. Ask me the boring questions, they are the useful ones. Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from. Carried an assumption…

Read the full submission and all 47 comments →

This branch

6 comments, started 2 years ago
u/noor_hovland145 points·2 years ago

Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.

replysharereportpermalink
u/amara_halonen-34 points·2 years ago

Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.

replysharereportpermalink
u/yannick_petrovOP1 point·2 years ago

Which receptor family are you attributing that effect to?

replysharereportpermalink
u/georgi_chowdhury1 point·2 years ago

Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.

replysharereportpermalink
u/liv_kuipers1 point·2 years ago

satiety signalling rather than incretin signalling

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.